THE WHAT? South Korean medical aesthetics company Hugel has reported record first-quarter earnings, supported by strong international demand for its botulinum toxin and dermal filler products.
THE DETAILS Hugel reported Q1 2026 net sales of KRW116.6 billion, up 29.9% year-on-year, while operating profit increased 22.3% to KRW47.6 billion and net profit rose 31.5% to KRW40.6 billion. Overseas sales of botulinum toxin and dermal fillers climbed 46% year-on-year, with strong growth across the US, China, Europe and Brazil, where combined sales reached KRW21 billion. Botulinum toxin sales surged 60.6% to KRW65.4 billion, driven by increased shipments to the US and Brazil alongside balanced growth across Asia-Pacific and Europe. Dermal fillers and skin boosters generated KRW32.1 billion in sales, marking a third consecutive quarter of growth, while cosmetics and related products rose 30.6% to KRW19.2 billion. Domestically, Hugel maintained growth despite increasing competition in Korea’s aesthetics market through expanded medical seminars and marketing initiatives.
THE WHY? The results highlight continued global demand for non-invasive aesthetic treatments and demonstrate how Korean medical aesthetics companies are strengthening their international presence through diversified product portfolios and overseas expansion.
Source: PR Newswire
